Paul S. Herendeen
2017 - Valeant Pharmaceuticals International
In 2017, Paul S. Herendeen earned a total compensation of $2.6M as Executive Vice President and Chief Financial Officer at Valeant Pharmaceuticals International, a 92% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $1,590,000 |
|---|---|
| Salary | $1,000,000 |
| Other | $7,950 |
| Total | $2,597,950 |
Herendeen received $1.6M in non-equity incentive plan, accounting for 61% of the total pay in 2017.
Herendeen also received $1M in salary and $8K in other compensation.
Rankings
In 2017, Paul S. Herendeen's compensation ranked 4,275th out of 14,666 executives tracked by ExecPay. In other words, Herendeen earned more than 70.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,275 out of 14,666 | 71st |
Division Manufacturing | 1,492 out of 5,748 | 74th |
Major group Chemicals And Allied Products | 427 out of 2,048 | 79th |
Industry group Drugs | 327 out of 1,704 | 81st |
Industry Pharmaceutical Preparations | 262 out of 1,313 | 80th |
Source: SEC filing on March 21, 2018.
Herendeen's colleagues
We found four more compensation records of executives who worked with Paul S. Herendeen at Valeant Pharmaceuticals International in 2017.
2017
William Humphries
Valeant Pharmaceuticals International
Group Chairman
2017
Joseph Papa
Valeant Pharmaceuticals International
Chief Executive Officer
2017
Thomas Appio
Valeant Pharmaceuticals International
Group Chairman
2017
Christina Ackermann
Valeant Pharmaceuticals International